Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, exercised stock options and subsequently sold 6,500 shares of common stock.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., exercised 6,500 stock options on November 10, 2025.
• The exercise price for these options was $0.06 per share.
• Immediately following the exercise, Moreadith sold all 6,500 acquired shares of common stock.
• The shares were sold at a weighted average price of $4.10 per share, with individual transactions ranging from $4.00 to $4.30.
• After these transactions, Moreadith's direct beneficial ownership of common stock is 0 shares.
• Moreadith still beneficially owns 391,186 stock options, which are fully vested.

Sentiment

Score: 5

Explanation: The transaction is a routine insider stock option exercise and subsequent sale, which is common for executive compensation and liquidity management. It does not inherently indicate a positive or negative outlook for the company.

Positives

• Chief Scientific Officer Randall Moreadith realized a gain by exercising options at $0.06 and selling shares at an average of $4.10.

Negatives

• Chief Scientific Officer Randall Moreadith sold all 6,500 shares acquired through option exercise, reducing his direct common stock ownership to zero.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the sale as a routine liquidity event for the executive, or potentially as a minor signal regarding management's confidence, though the latter is less likely given the nature of the transaction.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Scientific Officer exercised vested stock options and sold the acquired shares. Such transactions are common for executive compensation and personal financial planning and typically do not provide sufficient new information to alter an investment recommendation based solely on this filing.

Keywords

Serina Therapeutics, SER, Randall Moreadith, Insider Trading, Stock Option Exercise, Share Sale, Form 4, Chief Scientific Officer